- ALNY +1.31%
Search results
- 265.35Add to watchlist+3.44 (+1.31%)As of Thu. Sep 12, 2024 12:36 PM EDT · Nasdaq Real Time Price (USD) · Market open
- Open260.42High266.80Low259.99
- Mkt Cap34.07BP/E (TTM)N/ADiv & YieldN/A & N/A
- Prev. Close261.9152 Wk. Low141.9852 Wk. High287.55
What analysts are sayingTop storiesAlnylam Pharmaceuticals, Inc. (ALNY): Do Hedge Funds Recommend This Biotech Stock Now?Yahoo Finance · 4 days ago- ALNY +1.31%
ESC 2024: Amvuttra data signals positive prospects in cardiomyopathy for AlnylamYahoo Finance · 2 weeks agoBiotech IPO Hopefuls Ready Burst of Debuts After Rough StretchYahoo Finance · 1 week agoRelated stocks
16 hours ago · Alnylam Pharmaceuticals released the final results of a study that has it on track for expanded use of a key product. Expanded use could lead revenue to double or triple within the next two years. Analysts are raising their price targets and leading this market to another. 5 stocks we like better than Alnylam Pharmaceuticals
- Alnylam Pharmaceuticals (ALNY) Stock Forecast and Price ...
ALNY's current price target is $279.14. Learn why top...
- Alnylam Pharmaceuticals (ALNY) Stock Price, News & Analysis
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company,...
- Alnylam Pharmaceuticals (ALNY) Stock Forecast and Price ...
4 days ago · Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Number of Hedge Fund Holders: 53. One of the Best Biotech Stocks to Invest In According to Hedge Funds, a biopharmaceutical company, Alnylam ...
3 days ago · ALNY's current price target is $279.14. Learn why top analysts are making this stock forecast for Alnylam Pharmaceuticals at MarketBeat.
- (844) 978-6257
- 345 N Reid Place, Suite 620, Sioux Falls, 57103, SD
- investors@alnylam.com
People also ask
Who owns Alnylam Pharmaceuticals?
What does Alnylam Pharmaceuticals do?
How much did Alnylam Pharmaceuticals (ALNY) earn?
When is Alnylam Pharmaceuticals' next earnings announcement?
4 days ago · Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the ...
- US$285.00
- 0.37
- US$141.98
- US$272.64
1 day ago · Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
- investors@alnylam.com
- (617) 551-8200
- 2.1K
1 day ago · Stock analysis for Alnylam Pharmaceuticals Inc (ALNY:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.
2 days ago · Alnylam Pharma has been riding high since revealing top-line results from its HELIOS-B trial of vutrisiran in transthyretin-mediated amyloidosis (ATTR) – but a look at the full data seems to ...